Intercytex Group plc - Product Pipeline Review - Q4 2010

Date: December 1, 2010
Pages: 45
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: IE384BECABBEN
Leaflet:

Download PDF Leaflet

Intercytex Group plc – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Intercytex Group plc – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Intercytex Group plc – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Intercytex Group plc human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Intercytex Group plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Intercytex Group plc’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Intercytex Group plc’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Intercytex Group plc in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Intercytex Group plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Intercytex Group plc.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Intercytex Group plc and identify potential opportunities in those areas.
Intercytex Group plc Snapshot
Intercytex Group plc Overview
Key Information
Key Facts
Intercytex Group plc – Research and Development Overview
Key Therapeutic Areas
Intercytex Group plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Intercytex Group plc – Pipeline Products Glance
Intercytex Group plc – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Intercytex Group plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Intercytex Group plc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Intercytex Group plc – Drug Profiles
Cyzact
  Product Description
  Mechanism of Action
  R&D Progress
ICX-TRC
  Product Description
  Mechanism of Action
  R&D Progress
VAVELTA
  Product Description
  Mechanism of Action
  R&D Progress
ICX-SKN
  Product Description
  Mechanism of Action
  R&D Progress
VAVELTA
  Product Description
  Mechanism of Action
  R&D Progress
ICX-SKN
  Product Description
  Mechanism of Action
  R&D Progress
SHEF-1
  Product Description
  Mechanism of Action
  R&D Progress
Intercytex Group plc – Pipeline Analysis
Intercytex Group plc – Pipeline Products by Therapeutic Class
Intercytex Group plc – Pipeline Products by Route of Administration
Intercytex Group plc – Pipeline Products by Molecule Type
Intercytex Group plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 30, 2008: Intercytex Presents Positive Data From Phase II Clinical Trial Of VAVELTA
Sep 05, 2006: Intercytex Chronic Commences Phase II Trial Of Intercytex's ICX-PRO In Diabetic Foot Ulcers
Financial Deals Landscape
Intercytex Group plc, Deals Volume Summary, 2004 to YTD 2010
Intercytex Group plc, Deals Summary By Region, 2004 to YTD 2010
Intercytex Group plc, Deals Summary, 2004 to YTD 2010
Intercytex Group plc Detailed Deal Summary
Acquisition
Intercytex Group Acquires Axordia
Private Equity
Intercytex Raises $21.22 Million In Financing
Intercytex Group Secures $10.19 Million In Private Equity Financing
Venture Financing
Intercytex Secures $14.1 Million In Series C Financing
Intercytex Secures $2.23 Million In Seed Funding
Equity Offering
Intercytex Group Completes Private Placement Of $4.88 Million
Intercytex Group Completes Private Placement Of $23.93 Million
Intercytex Group Completes Initial Public Offering Of $26.79 Million
Baxter International Enters Into Licensing Agreement With Intercytex
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 45

LIST OF TABLES

Intercytex Group plc – Pipeline by Therapy Area and Indication, 2010
Intercytex Group plc – Pipeline by Stage of Development, 2010
Intercytex Group plc – Monotherapy Products in Pipeline, 2010
Intercytex Group plc – Phase III, 2010
Intercytex Group plc - Phase II, 2010
Intercytex Group plc - Phase I, 2010
Intercytex Group plc - Pipeline By Therapeutic Class, 2010
Intercytex Group plc – Pipeline By Route of Administration, 2010
Intercytex Group plc – Pipeline By Molecule Type, 2010
Intercytex Group plc, Other Locations
Intercytex Group plc, Subsidiaries
Intercytex Group plc, Deals Summary, 2004 to YTD 2010
Intercytex Group plc, Deals Summary by Region, 2004 to YTD 2010
Intercytex Group plc, Deals Summary, 2004 to YTD 2010
Intercytex Group Acquires Axordia
Intercytex Raises $21.22 Million In Financing
Intercytex Group Secures $10.19 Million In Private Equity Financing
Intercytex Secures $14.1 Million In Series C Financing
Intercytex Secures $2.23 Million In Seed Funding
Intercytex Group Completes Private Placement Of $4.88 Million
Intercytex Group Completes Private Placement Of $23.93 Million
Intercytex Group Completes Initial Public Offering Of $26.79 Million
Baxter International Enters Into Licensing Agreement With Intercytex 43

LIST OF FIGURES

Intercytex Group plc – Pipeline by Therapy Area and Indication, 2010
Intercytex Group plc – Pipeline by Stage of Development, 2010
Intercytex Group plc – Monotherapy Products in Pipeline, 2010
Intercytex Group plc – Pipeline By Therapeutic Class, 2010
Intercytex Group plc – Pipeline By Route of Administration, 2010
Intercytex Group plc – Pipeline By Molecule Type, 2010 23

Ask Your Question

Intercytex Group plc - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: